BR112014016887A2 - potencialização do transporte de moléculas terapêu-ticas através da barreira hematoencefálica - Google Patents
potencialização do transporte de moléculas terapêu-ticas através da barreira hematoencefálicaInfo
- Publication number
- BR112014016887A2 BR112014016887A2 BR112014016887A BR112014016887A BR112014016887A2 BR 112014016887 A2 BR112014016887 A2 BR 112014016887A2 BR 112014016887 A BR112014016887 A BR 112014016887A BR 112014016887 A BR112014016887 A BR 112014016887A BR 112014016887 A2 BR112014016887 A2 BR 112014016887A2
- Authority
- BR
- Brazil
- Prior art keywords
- transport
- blood
- brain barrier
- enhancement
- therapeutic molecules
- Prior art date
Links
- 230000008499 blood brain barrier function Effects 0.000 title abstract 4
- 210000001218 blood-brain barrier Anatomy 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
resumo "potencialização do transporte de moléculas terapêuticas através da barreira hematoencefálica". a invenção baseia-se, pelo menos em parte, na constatação de que uma versão dimérica de um anticorpo de transmigração da bbb (por exemplo, constatou-se que o anticorpo de ligação tmem30a (cdc-50a) fc5) potencializa consideravelmente o transporte através da bbb em comparação ao fc5 vhh monovalente. a invenção fornece, nomeadamente, moléculas que aumentam o transporte de agentes farmacologicamente ativos através da barreira hematoencefálica, métodos para aumentar o transporte através da barreira hematoencefálica e métodos de tratamento de distúrbios ou doenças tendo um componente neurológico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261585039P | 2012-01-10 | 2012-01-10 | |
PCT/US2013/021041 WO2013106577A2 (en) | 2012-01-10 | 2013-01-10 | Enhancement of transport of therapeutic molecules across the blood brain barrier |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014016887A2 true BR112014016887A2 (pt) | 2018-08-14 |
Family
ID=47633561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014016887A BR112014016887A2 (pt) | 2012-01-10 | 2013-01-10 | potencialização do transporte de moléculas terapêu-ticas através da barreira hematoencefálica |
Country Status (25)
Country | Link |
---|---|
US (1) | US9676849B2 (pt) |
EP (1) | EP2802606B1 (pt) |
JP (1) | JP6247226B2 (pt) |
KR (1) | KR102104686B1 (pt) |
CN (1) | CN104159922B (pt) |
AU (1) | AU2013207927B2 (pt) |
BR (1) | BR112014016887A2 (pt) |
CA (1) | CA2860579A1 (pt) |
CY (1) | CY1120419T1 (pt) |
DK (1) | DK2802606T3 (pt) |
EA (1) | EA201491346A1 (pt) |
ES (1) | ES2677111T3 (pt) |
HK (1) | HK1203977A1 (pt) |
HR (1) | HRP20180937T1 (pt) |
HU (1) | HUE039033T2 (pt) |
IL (1) | IL233246B (pt) |
LT (1) | LT2802606T (pt) |
MX (1) | MX350378B (pt) |
NZ (1) | NZ626620A (pt) |
PL (1) | PL2802606T3 (pt) |
PT (1) | PT2802606T (pt) |
SI (1) | SI2802606T1 (pt) |
TR (1) | TR201809743T4 (pt) |
WO (1) | WO2013106577A2 (pt) |
ZA (1) | ZA201404873B (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013285422B2 (en) | 2012-07-04 | 2017-04-27 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
BR112016013849A2 (pt) * | 2014-01-03 | 2017-10-10 | Hoffmann La Roche | conjugados de anticorpos biespecíficos antihapteno/antirreceptores da barreira hematoencefálica, seus usos, e formulação farmacêutica |
RU2694981C2 (ru) | 2014-01-03 | 2019-07-18 | Ф. Хоффманн-Ля Рош Аг | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения |
EP3089759B1 (en) | 2014-01-03 | 2018-12-05 | F. Hoffmann-La Roche AG | Covalently linked polypeptide toxin-antibody conjugates |
EP3114140B1 (en) * | 2014-03-06 | 2019-02-27 | National Research Council of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
PE20161311A1 (es) * | 2014-03-06 | 2016-11-25 | Nat Res Council Canada | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. |
KR102355308B1 (ko) * | 2014-03-06 | 2022-01-24 | 내셔날 리서치 카운실 오브 캐나다 | 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도 |
JP6391318B2 (ja) * | 2014-06-27 | 2018-09-19 | 学校法人順天堂 | アルツハイマー病予防治療薬のスクリーニング法 |
ES2924282T3 (es) * | 2014-12-19 | 2022-10-05 | Medimmune Ltd | Moléculas de transporte a través de la barrera hematoencefálica y usos de las mismas |
SG11201705986QA (en) | 2015-01-29 | 2017-08-30 | Technophage Investigação E Desenvolvimento Em Biotecnologia Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
EP3481870A4 (en) * | 2016-07-06 | 2020-03-11 | National Research Council of Canada | HUMANIZED ANTIBODIES CROSSING THE HEMATOENCEPHALIC BARRIER AND USES THEREOF |
WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
US10906973B2 (en) | 2016-12-12 | 2021-02-02 | National Research Council Of Canada | Antibody variants transmigrating the blood-brain barrier and uses thereof |
CN110382522A (zh) * | 2017-01-30 | 2019-10-25 | 加拿大国家研究委员会 | 血脑屏障穿过化合物及其用途 |
US11453701B2 (en) | 2017-08-18 | 2022-09-27 | Adrx, Inc. | Tau aggregation peptide inhibitors |
AU2018396970A1 (en) | 2017-12-28 | 2020-08-13 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against TIGIT |
US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
US11952432B2 (en) | 2018-02-07 | 2024-04-09 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
US20210340272A1 (en) * | 2018-06-18 | 2021-11-04 | Anwita Biosciences, Inc. | Anti-mesothelin constructs and uses thereof |
US20210161993A1 (en) * | 2018-09-12 | 2021-06-03 | Pvp Labs Pte. Ltd. | Method for accelerated healing of burn wounds |
JP2022508609A (ja) | 2018-10-04 | 2022-01-19 | ユニバーシティ オブ ロチェスター | 血漿浸透圧を操作することによるグリンパティック送達の改善 |
KR20210111242A (ko) * | 2018-10-29 | 2021-09-10 | 바이오젠 엠에이 인코포레이티드 | 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체 |
JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Her2を標的とする免疫結合体 |
CN113284553B (zh) * | 2021-05-28 | 2023-01-10 | 南昌大学 | 一种用于治疗药物成瘾的药物靶点结合能力测试方法 |
WO2023097605A1 (en) * | 2021-12-02 | 2023-06-08 | Linno Pharmaceuticals Inc. | Transferrin binding antibodies and use thereof |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1166947A (en) | 1914-10-05 | 1916-01-04 | Paramount Hosiery Form Drying Company | Hosiery-finishing apparatus. |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
US4849407A (en) | 1986-08-13 | 1989-07-18 | Zymogenetics, Inc. | Biologically active mosaic proteins |
US5157021A (en) | 1985-03-15 | 1992-10-20 | Novo Nordisk A/S | Insulin derivatives and pharmaceutical preparations containing these derivatives |
US4745055A (en) | 1985-05-07 | 1988-05-17 | California Biotechnology Inc. | Fused protein for enzyme immunoassay system |
IL78444A (en) | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
CA1340456C (en) | 1986-07-07 | 1999-03-23 | Hubert J.P. Schoemaker | Chimeric rodent/human immunoglobulins specific for tumor-associated antigens |
NO873164L (no) | 1986-07-30 | 1988-02-01 | Teijin Ltd | Muse-humane kimaere antistoffer. |
IL84285A (en) | 1986-10-27 | 1993-03-15 | Int Genetic Engineering | Chimeric antibody with specificity to human tumor antigen |
GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
CA1339445C (en) | 1986-11-12 | 1997-09-09 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and method of use |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ES2057571T3 (es) | 1989-05-22 | 1994-10-16 | Zymogenetics Inc | Receptor de pdgf-alfa. |
US5061786A (en) | 1989-05-25 | 1991-10-29 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
EP1132471A3 (de) | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
CA2040099A1 (en) | 1990-05-01 | 1991-11-02 | Mariano Barbacid | Tyrosine kinase negative trkb |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5453491A (en) | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
JPH04334377A (ja) | 1990-12-31 | 1992-11-20 | Akzo Nv | 酸−不安定性リンカー分子 |
US5541063A (en) | 1991-04-19 | 1996-07-30 | Schering Corporation | Human interleukin-3 receptor α subunit |
US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
US5348856A (en) | 1991-07-08 | 1994-09-20 | E. R. Squibb & Sons, Inc. | DNA encoding TRKC protein |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
PT848755E (pt) | 1995-09-08 | 2003-12-31 | Genentech Inc | Proteina relacionada com o vegf |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
IL127558A0 (en) | 1996-07-03 | 1999-10-28 | Genentech Inc | Hepatocyte growth factor receptor agonists and uses thereof |
US6159462A (en) | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
CA2264610A1 (en) | 1996-11-05 | 1998-05-14 | Bristol-Myers Squibb Company | Branched peptide linkers |
EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
ES2301198T3 (es) | 1997-06-12 | 2008-06-16 | Novartis International Pharmaceutical Ltd. | Polipeptidos artificiales de anticuerpos. |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
DE60042550D1 (de) | 1999-01-06 | 2009-08-27 | Genentech Inc | Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i) |
AU762351B2 (en) | 1999-01-06 | 2003-06-26 | Genentech Inc. | Insulin-like growth factor (IGF) I mutant variants |
US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
CA2441903C (en) | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
DE60140474D1 (de) | 2000-09-08 | 2009-12-24 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
DK1390535T3 (da) | 2001-04-26 | 2010-12-06 | Amgen Mountain View Inc | Kombinatoriske biblioteker af monomer-domæner |
AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
EP1773872B1 (en) | 2004-05-21 | 2017-03-15 | The Uab Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
AU2005307789A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
WO2007036021A1 (en) | 2005-09-27 | 2007-04-05 | National Research Council Of Canada | Blood-brain barrier epitopes and uses thereof |
EP1986684A2 (en) * | 2006-02-15 | 2008-11-05 | ImClone Systems Incorporated | Functional antibodies |
US20090252729A1 (en) | 2007-05-14 | 2009-10-08 | Farrington Graham K | Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto |
PE20130527A1 (es) * | 2010-03-03 | 2013-05-09 | Boehringer Ingelheim Int | Polipeptidos de union a a-beta biparatopicos |
CA2796215C (en) | 2010-04-14 | 2021-05-18 | National Research Council Of Canada | Compositions and methods for brain delivery of analgesic peptides |
-
2013
- 2013-01-10 CA CA2860579A patent/CA2860579A1/en active Pending
- 2013-01-10 AU AU2013207927A patent/AU2013207927B2/en active Active
- 2013-01-10 KR KR1020147018724A patent/KR102104686B1/ko active IP Right Grant
- 2013-01-10 HU HUE13702529A patent/HUE039033T2/hu unknown
- 2013-01-10 WO PCT/US2013/021041 patent/WO2013106577A2/en active Application Filing
- 2013-01-10 BR BR112014016887A patent/BR112014016887A2/pt not_active Application Discontinuation
- 2013-01-10 MX MX2014008365A patent/MX350378B/es active IP Right Grant
- 2013-01-10 CN CN201380004989.7A patent/CN104159922B/zh active Active
- 2013-01-10 EP EP13702529.2A patent/EP2802606B1/en active Active
- 2013-01-10 TR TR2018/09743T patent/TR201809743T4/tr unknown
- 2013-01-10 EA EA201491346A patent/EA201491346A1/ru unknown
- 2013-01-10 PT PT137025292T patent/PT2802606T/pt unknown
- 2013-01-10 US US14/370,828 patent/US9676849B2/en active Active
- 2013-01-10 ES ES13702529.2T patent/ES2677111T3/es active Active
- 2013-01-10 SI SI201331060T patent/SI2802606T1/en unknown
- 2013-01-10 PL PL13702529T patent/PL2802606T3/pl unknown
- 2013-01-10 DK DK13702529.2T patent/DK2802606T3/en active
- 2013-01-10 JP JP2014552303A patent/JP6247226B2/ja active Active
- 2013-01-10 NZ NZ626620A patent/NZ626620A/en unknown
- 2013-01-10 LT LTEP13702529.2T patent/LT2802606T/lt unknown
-
2014
- 2014-06-19 IL IL233246A patent/IL233246B/en active IP Right Grant
- 2014-07-01 ZA ZA2014/04873A patent/ZA201404873B/en unknown
-
2015
- 2015-05-11 HK HK15104429.6A patent/HK1203977A1/xx unknown
-
2018
- 2018-06-18 HR HRP20180937TT patent/HRP20180937T1/hr unknown
- 2018-07-11 CY CY20181100721T patent/CY1120419T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
IL233246A0 (en) | 2014-08-31 |
ZA201404873B (en) | 2018-12-19 |
EP2802606B1 (en) | 2018-04-25 |
WO2013106577A3 (en) | 2013-11-21 |
AU2013207927B2 (en) | 2017-11-02 |
TR201809743T4 (tr) | 2018-07-23 |
AU2013207927A1 (en) | 2014-07-17 |
KR20140112497A (ko) | 2014-09-23 |
HK1203977A1 (en) | 2015-11-06 |
NZ626620A (en) | 2016-07-29 |
WO2013106577A2 (en) | 2013-07-18 |
JP6247226B2 (ja) | 2017-12-13 |
JP2015509097A (ja) | 2015-03-26 |
MX2014008365A (es) | 2014-10-06 |
CN104159922B (zh) | 2018-03-02 |
DK2802606T3 (en) | 2018-06-25 |
CY1120419T1 (el) | 2019-07-10 |
HUE039033T2 (hu) | 2018-12-28 |
CN104159922A (zh) | 2014-11-19 |
PT2802606T (pt) | 2018-07-13 |
HRP20180937T1 (hr) | 2018-08-10 |
EA201491346A1 (ru) | 2014-11-28 |
US20150210762A1 (en) | 2015-07-30 |
PL2802606T3 (pl) | 2018-09-28 |
EP2802606A2 (en) | 2014-11-19 |
KR102104686B1 (ko) | 2020-04-24 |
US9676849B2 (en) | 2017-06-13 |
LT2802606T (lt) | 2018-10-10 |
IL233246B (en) | 2018-07-31 |
MX350378B (es) | 2017-09-05 |
SI2802606T1 (en) | 2018-08-31 |
ES2677111T3 (es) | 2018-07-30 |
CA2860579A1 (en) | 2013-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014016887A2 (pt) | potencialização do transporte de moléculas terapêu-ticas através da barreira hematoencefálica | |
EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
EA201000603A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ | |
BR112015022465A2 (pt) | método para tratamento não-tóxico para síndrome de abstinência de drogas | |
EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
UA114891C2 (uk) | ІЗОЛЬОВАНЕ АНТИТІЛО ЛЮДИНИ, ЯКЕ СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З АНГІОПОЕТИНПОДІБНИМ БІЛКОМ 3 ЛЮДИНИ (hАNGPTL3), ТА ЙОГО ЗАСТОСУВАННЯ | |
BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
CO6390109A2 (es) | Inhibidores de syk de imidazopirazina | |
BR112012022223A2 (pt) | formulações de proteína concentrada e usos das mesmas | |
BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
BR112015006093A2 (pt) | combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington | |
BR112014008036A2 (pt) | tratamento de rinite | |
BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
EA201492067A1 (ru) | Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта | |
BR112015000808A2 (pt) | regime de dosagem para inibidores de janus quinase (jak) | |
GB2496794A (en) | Combination pharmaceutical composition and methods of treating and methods of treating functional diseases or conditions of gastrointestinal tract | |
EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
BR112016013961A2 (pt) | angiotensina ii sozinha ou em combinação para o tratamento da hipotensão | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
BR112015004119A2 (pt) | anticorpos monoclonais para melhorar ou inibir o fator de crescimento semelhante à insulina tipo 1 (igf-1) | |
BR112015014261A8 (pt) | composto de danazol, seu uso e formulação farmacêutica compreendendo este | |
BR112014015578A2 (pt) | composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide | |
BR112015012497A2 (pt) | combinações farmacêuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: BIOGEN MA INC. (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |